A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE)—commonly referred to as blockage of arteries and blood clots, respectively—associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives.
